Results 111 to 120 of about 21,748 (299)

Is AMP‐activated protein kinase activation a central mechanism of cardio‐metabolic outcomes after metabolic and bariatric surgery?

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity. It usually results in spectacular weight loss, associated with improvements of obesity‐associated comorbidities. The mechanisms underlying these benefits are not fully understood but could involve a postoperative activation of the enzyme 5′ AMP‐activated ...
Adrien Delcour, Nathalie Niederhoffer
wiley   +1 more source

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus

Терапевтический архив, 2014
AIM. To study the secretion of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 2 (GLP-2) in response to a carbohydrate load in people with risk factors for type 2 diabetes mellitus (DM2) in ...
E A Shestakova, A V Il'in, M V Shestakova, I I Dedov   +3 more
doaj  

HNF4A mutation: switch from hyperinsulinaemic hypoglycaemia to maturity-onset diabetes of the young, and incretin response [PDF]

, 2014
This is a freely-available open access publication. Please cite the published version which is available via the DOI link in this recordHepatocyte nuclear factor 4α (HNF4A) is a member of the nuclear receptor family of ligand-activated transcription ...
Alberti, Colclough, Drucker, Fajans, Flanagan, Heinze, Herman, Herzberg-Schafer, Huml, Kapoor, Kuo, Odom, Olson, Pearson, Rask, Robertson, Sladek, Wang, Xanthopoulos, Yamagata   +19 more
core   +1 more source

Rationale and design of a parallel randomised trial of a plant‐based intensive lifestyle intervention for diabetes remission: The REmission of diabetes using a PlAnt‐based weight loss InteRvention (REPAIR) trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target. Current evidence supports bariatric surgery and low‐calorie diets with meal replacements.
Brighid McKay, Dayana El Chaar, Melanie Paquette, Michael Vallis, Diana Sherifali, Paul Oh, Susan Marzolini, Kaberi Dasgupta, Gillian Booth, Mike Lean, Hertzel C. Gerstein, Jordi Salas‐Salvadó, Jacqueline L. Beaudry, Christopher P. F. Marinangeli, Russell J. de Souza, Lawrence A. Leiter, Cyril W. C. Kendall, David J. A. Jenkins, John L. Sievenpiper, Laura Chiavaroli   +19 more
wiley   +1 more source

A Multifunctional Bread Rich in Beta Glucans and Low in Starch Improves Metabolic Control in Type 2 Diabetes: A Controlled Trial [PDF]

, 2017
: Design: Functional foods may be useful for people with diabetes. The soluble fibers beta glucans can modify starch digestion and improve postprandial glucose response.
Lante, Anna, Tessari, Paolo
core   +2 more sources

A treat‐to‐target approach for obesity management: A post hoc analysis of the SURMOUNT‐5 trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Introduction With new advancements in obesity medicine, clarity on goals and expectations for successful disease management is limited. This post hoc analysis assessed application of proposed treat‐to‐target (TtT) thresholds for obesity to the outcome measures of SURMOUNT‐5, which randomised participants with obesity to tirzepatide or ...
Carel W. le Roux, Luca Busetto, Louis Aronne, Deborah Bade Horn, Georgios K. Dimitriadis, Beverly Falcon, Luis‐Emilio Garcia‐Perez, Elisa Gomez Valderas, Theresa Hunter Gibble, Cagri Senyucel, Julia P. Dunn   +10 more
wiley   +1 more source

The integrated incretin effect is reduced by both glucose intolerance and obesity in Japanese subjects

Frontiers in Endocrinology
IntroductionIncretin-based drugs are extensively utilized in the treatment of type 2 diabetes (T2D), with remarkable clinical efficacy. These drugs were developed based on findings that the incretin effect is reduced in T2D.
Akihiro Hamasaki, Akihiro Hamasaki, Norio Harada, Atsushi Muraoka, Shunsuke Yamane, Erina Joo, Kazuyo Suzuki, Nobuya Inagaki   +7 more
doaj   +1 more source

Metabolic Comparison of One-Anastomosis Gastric Bypass, Single-Anastomosis Duodenal-Switch, Roux-en-Y Gastric Bypass, and Vertical Sleeve Gastrectomy in Rat [PDF]

, 2018
Background One-anastomosis gastric bypass (OAGB) and single-anastomosis duodenal switch (SADS) have become increasingly popular weight loss strategies. However, data directly comparing the effectiveness of these procedures with Roux-en-Y gastric bypass ...
Arble, Deanna M., Bozadjieva, Nadajda, Evers, Simon S., Frikke-Schmidt, Henriette, Lewis, Alfor, Myronovych, Andriy, Seeley, Randy J., Toure, Mouhamadoul Habib   +7 more
core   +1 more source

Safety, feasibility, and dose‐dependent metabolic effects of endoscopic duodenal pulsed electric field therapy in adults with type 2 diabetes: Results from two multicentre proof‐of‐concept studies

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The duodenum plays a central role in metabolic regulation, influencing insulin sensitivity, and glucose homeostasis. In type 2 diabetes (T2D), structural and functional abnormalities of the duodenal mucosa (“diabetic duodenopathy”) are increasingly recognized as contributors to insulin resistance and dysglycaemia.
David N. O'Neal, Adrian Sartoretto, Bronte A. Holt, Barham K. Abu Dayyeh, Rhys Vaughan, Georgina Cameron, Sujievvan Chandran, Alexander J. Thompson, Howard McCollister, Paul Severson, Andrew C. Storm, Lian Cunningham, Elif I. Ekinci   +12 more
wiley   +1 more source

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source